Catalog No.
Product Name
Application
Product Information
Citations
-
COX Inhibitor
Thiazolinobutazone is a selective cyclooxygenase (COX) inhibitor that exhibits anti-inflammatory properties. This compound is recognized for its reduced toxicity compared to Phenylbutazone, making it a safer alternative in pharmacological research. Thiazolinobutazone is primarily utilized in the investigation of various immunological diseases, providing insights into COX-related pathways and inflammation mechanisms. -
Antioxidant/Anti-inflammatory/Antipyretic/Analgesic Agent
β-Selinene is a sesquiterpene that acts as a potent antioxidant, anti-inflammatory, antipyretic, and analgesic agent. It demonstrates significant antioxidant activity by scavenging free radicals and chelating pro-oxidative metal ions. Additionally, β-selinene inhibits cyclooxygenase (COX) activity and reduces the synthesis of pro-inflammatory prostaglandins, contributing to its anti-inflammatory properties. Furthermore, it regulates the thermoregulatory set point in the hypothalamus while inhibiting inflammatory mediators, providing antipyretic and analgesic effects. This compound is valuable for research applications focused on oxidative stress, inflammation, and pain management. -
Anti-inflammatory Agent
Isonixin is a non-steroidal anti-inflammatory agent that targets cyclooxygenase enzymes. Its primary biological activity involves the inhibition of prostaglandin synthesis, leading to reduced inflammation and pain. Isonixin is widely used in research applications focused on elucidating mechanisms of pain and inflammatory responses, making it a valuable tool for scientific studies in these areas. -
COX Inhibitor
LY150310 free base is a potent COX inhibitor that effectively inhibits thromboxane synthase and cyclooxygenase, as well as thrombin activation. This compound demonstrates a dose-dependent ability to inhibit spontaneous lung metastasis, making it valuable for research applications aimed at understanding metastatic processes and developing anti-cancer therapies. -
COX-2 Inhibitor
COX-2-IN-12 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 19.98 μM, demonstrating potent anti-inflammatory properties. This compound is suitable for various biological research applications related to inflammation and pain management. In vivo acute toxicity studies indicate a favorable safety profile for COX-2-IN-12, supporting its potential for therapeutic exploration. -
Anti-inflammatory Agent
Anti-inflammatory agent 8 is a tilomisole-based benzimidazothiazole derivative targeting the COX-2 enzyme with enhanced selectivity over COX-1, exhibiting an IC50 of 0.09 nM. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into mechanisms of inflammation and related pathophysiological conditions. Its oral bioavailability supports its utility in in vivo studies. -
COX-1 Inhibitor
(+)-Catechin pentaacetate serves as a precursor for the synthesis of (+)-catechin, a natural compound with herbicidal and antimicrobial properties. This compound functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 1.4 μM. Its ability to modulate COX-1 activity makes it valuable for research in inflammation and pain response pathways. -
COX-2 Inhibitor
COX-2-IN-23 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting IC50 values of 0.28 μM for COX-2 and 20.14 μM for COX-1. This compound demonstrates significant anti-inflammatory activity while maintaining a low ulcerogenic profile, making it suitable for research applications focused on inflammation and pain modulation. Its selectivity and efficacy position it as a valuable tool in the study of inflammatory pathways. -
COX Inhibitor
COX-2-IN-50 is a highly soluble COX-2 inhibitor, exhibiting notable analgesic activity. With a water solubility of 20.3 mg/mL, it surpasses its precursor compound, PC407, which has a solubility of 1.6 μg/mL. This compound demonstrates excellent biocompatibility, making it suitable for the formulation of injectable dosage forms. COX-2-IN-50 has shown significant analgesic effects in vivo, indicating its potential in pain management research and therapeutic applications. -
COX Inhibitor
Diclofenac deanol is a potent cyclooxygenase (COX) inhibitor, particularly exhibiting enhanced selectivity for COX-2 over COX-1. This compound possesses anti-inflammatory, analgesic, and antipyretic properties, making it valuable in pain management and inflammation-related research. Its superior water solubility compared to traditional diflunisal salts facilitates its application in various biological assays and medical research, expanding its potential therapeutic uses. -
COX-2 Inhibitor
COX-2-IN-20 is a selective COX-2 inhibitor with a measured IC50 of 17.9 nM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research in inflammation and pain management. Its oral bioavailability allows for convenient administration in various studies aimed at understanding COX-2's role in inflammatory diseases. -
Anti-inflammatory Agent
Cinmetacin is an orally active anti-inflammatory agent that selectively targets cyclooxygenase (COX). Its mechanism of action involves the inhibition of prostaglandin synthesis, making it effective in modulating inflammatory responses. This compound shows promise for research applications related to inflammatory diseases, including arthritis, by providing insights into COX-mediated pathways and potential therapeutic interventions. -
COX Inhibitor
Flunixin is a cyclooxygenase (COX) inhibitor that exhibits IC50 values of 0.55 μM for COX-1 and 3.24 μM for COX-2. It is known for its anti-inflammatory properties, making it valuable in studies aimed at understanding inflammatory pathways. Flunixin is commonly utilized in research focused on pain management and related therapeutic applications. -
COX-2 Inhibitor
COX-2-IN-22 is a selective inhibitor of Cyclooxygenase-2 (COX-2) with an IC50 of 8.6 µM. In addition to its primary activity, COX-2-IN-22 also exhibits inhibitory effects on Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), β-Secretase, Lipoxygenase-5 (LOX-5), and DPPH, with IC50 values of 2.8 µM, 6.3 µM, 15.3 µM, 13.9 µM, and 6.8 µM, respectively. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research in neuroinflammatory and neurodegenerative disease models. -
COX Inhibitor
2-Hydroxy Ibuprofen is a metabolic derivative of Ibuprofen, functioning primarily as a cyclooxygenase (COX) inhibitor. It demonstrates significant anti-inflammatory activity, targeting COX-1 and COX-2 enzymes with inhibitory concentrations (IC50) of 13 μM and 370 μM, respectively. This compound is valuable for studying the mechanisms of inflammation and pain in various research applications, particularly in pharmacology and toxicology. -
Anti-inflammatory Agent
Buddlejasaponin IV is an anti-inflammatory agent that demonstrates cytotoxic effects on cancer cells. This compound modulates inflammatory pathways, making it a valuable tool in research focused on inflammation-related diseases and cancer therapies. Its biological activity supports investigations into therapeutic strategies for managing inflammation and tumorigenesis. -
COX-2 Inhibitor
Etoricoxib hydrochloride is a selective COX-2 inhibitor that effectively reduces inflammation and alleviates pain by blocking the conversion of arachidonic acid to prostaglandins. This compound is primarily utilized in research related to osteoarthritis and demonstrates significant anti-inflammatory properties. Additionally, etoricoxib hydrochloride has been shown to promote bone remodeling through enhanced alkaline phosphatase activity. Its formulation, developed using emulsion solvent evaporation technology, ensures good cell compatibility for various biological applications. -
COX-2 Inhibitor
Indomethacin heptyl ester is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.04 μM. This compound demonstrates significant anti-inflammatory activity, making it valuable for studying inflammatory processes and discovering potential therapeutic interventions in diseases characterized by COX-2 overexpression. Its specificity for COX-2 provides insights into the mechanism of action and the development of novel anti-inflammatory agents. -
COX Inhibitor
Indobufen sodium is a reversible inhibitor of cyclooxygenase (COX) activity, primarily targeting platelet aggregation. By suppressing the synthesis of thromboxane A2 (TxA2), it effectively modulates platelet function. Additionally, Indobufen sodium down-regulates the expression of tissue factor (TF) in monocytes, making it a valuable tool for research involving cardiovascular and inflammatory processes. -
COX-2/Aromatase Inhibitor
COX-2/Aromatase-IN-2 is a potent dual inhibitor targeting cyclooxygenase-2 (COX-2) and aromatase. It effectively suppresses inflammation and inhibits cell proliferation in breast cancer models, demonstrating significant anti-cancer and anti-inflammatory activities. Proven efficacy in the MCF-7 breast cancer cell line and carrageenan-induced rat paw edema model makes COX-2/Aromatase-IN-2 a valuable tool for researching inflammation and breast cancer pathways. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX Inhibitor
Axinelline A is a potent cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.22 μM for COX-2 and 8.89 μM for COX-1. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and potential therapeutic interventions. Axinelline A is suitable for studies focused on the modulation of COX enzymes and the inflammatory response. -
COX-2 Inhibitor
DRF-4848 is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme involved in the inflammatory response. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studying inflammation-related pathways and diseases. Researchers can utilize DRF-4848 to investigate its effects on pain management and the modulation of inflammatory processes in various biological contexts. -
COX-2 Inhibitor
COX-2-IN-26 is a selective and orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.067 µM, demonstrating its potency. This compound exhibits anti-inflammatory properties, making it a valuable tool for research in inflammation-related studies. Additionally, COX-2-IN-26 is noted for its favorable gastrointestinal safety profile, supporting its potential application in therapeutic development. -
COX-2 Inhibitor
Anti-inflammatory agent 56 is a selective COX-2 inhibitor with an IC50 of 0.54 μM. It demonstrates significant anti-inflammatory and antioxidant properties, effectively reducing oxidative stress-induced cell death. By inhibiting key targets such as Keap1, COX-2, and iNOS, this compound mitigates neuroinflammation and oxidative stress. Furthermore, it exhibits low acute toxicity in murine models, with an LD50 of 1000 mg/kg, making it a valuable tool for research in inflammation and neuroprotection. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
COX Inhibitor
N-(4-acetamidophenyl)-indomethacin amide is a selective reversible inhibitor of cyclooxygenase-2 (COX-2). It demonstrates potent inhibitory activity against human recombinant and ovine COX-2, with IC50 values of 0.12 μM and 0.625 μM, respectively, while showing significantly lower potency against COX-1 isoforms. This compound is valuable for research applications focused on inflammation, pain management, and the role of COX-2 in various pathological conditions. -
Nonsteroidal Anti-Inflammatory Drug
Miroprofen is an orally active nonsteroidal anti-inflammatory drug (NSAID) that functions primarily as an analgesic. It demonstrates significant anti-inflammatory and analgesic properties, along with anti-platelet activity. Miroprofen is utilized in research applications aimed at understanding pain mechanisms and the role of inflammation in various disease models. -
Anti-inflammatory Agent
Anti-inflammatory agent 10 is a tilomisole-based benzimidazothiazole derivative designed to selectively inhibit the COX-2 enzyme over COX-1. This selectivity contributes to its anti-inflammatory properties, making it a valuable tool for research on inflammation-related pathways. Anti-inflammatory agent 10 is orally active, facilitating in vivo studies targeting inflammation and related diseases. -
Anti-inflammatory Agent
(S)-Otenaproxesul is an anti-inflammatory agent that primarily targets cyclooxygenase enzymes. It has demonstrated potential protective effects against gastric damage, making it a valuable substance for research into gastrointestinal health. This compound is suitable for studies investigating inflammation-related conditions and the development of novel therapeutic strategies. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
Nonsteroidal Anti-inflammatory Agent
Oxindanac is a nonsteroidal anti-inflammatory agent that primarily targets the inhibition of serum thromboxane B2 (TxB2) production. This compound effectively reduces edema and demonstrates significant analgesic properties. Oxindanac is utilized in research to study inflammation and pain management pathways, contributing valuable insights into therapeutic strategies for various inflammatory conditions. -
COX-2 Inhibitor
COX-2-IN-33 is a selective COX-2 inhibitor with an IC50 of 45.5 nM, designed for research into inflammatory pathways. This compound demonstrates significant inhibition of pro-inflammatory cytokine production in vivo, indicating its potential as an anti-inflammatory agent while maintaining gastric safety. It is particularly useful for studies focused on chronic inflammation and pain management. -
COX Inhibitor
4'-Aarboxylic acid imrecoxib is a metabolite of Imrecoxib, targeting the cyclooxygenase-2 (COX-2) enzyme. It exhibits anti-inflammatory properties through the inhibition of COX-2, making it valuable for research in pain management and inflammatory disorders. This compound can be utilized in studies focused on the modulation of prostaglandin synthesis. -
COX Inhibitor
Eltenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as a cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood. Its potent inhibitory activity against COX enzymes makes it valuable in studying inflammatory pathways and evaluating potential therapeutic applications related to pain and inflammation management. Researchers can utilize Eltenac in various experimental settings to explore the role of COX in disease processes. -
COX Inhibitor
Butanixin is a cyclooxygenase (COX) inhibitor that demonstrates significant anti-inflammatory and analgesic properties through the reduction of prostaglandin synthesis. This compound is primarily utilized in the research of musculoskeletal disorders, providing valuable insights into therapeutic mechanisms targeting inflammation and pain management. Its effectiveness in modulating COX activity makes it a relevant tool for investigating inflammatory pathways. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
Analgesic Antiinflammatory Agent
Tomoxiprole is an analgesic anti-inflammatory agent that selectively inhibits cyclooxygenase-2, with an IC50 value of 7 nM. Its precise inhibition of this enzyme leads to reduced inflammatory responses and pain relief. Tomoxiprole is primarily utilized in research focused on pain management and the modulation of inflammatory pathways. -
Anti-inflammatory Agent
Anti-inflammatory agent 9 is a tilomisole-based benzimidazothiazole derivative that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme over cyclooxygenase-1 (COX-1). This compound demonstrates significant anti-inflammatory activity, making it a valuable tool in the study of inflammation-related pathways and therapeutic interventions. Its oral bioavailability facilitates in vivo research applications, contributing to investigations in both pharmacology and medicinal chemistry. -
Anti-inflammatory Agent
MBL-1 is an orally active anti-inflammatory agent that targets the hCOX-2 protein, demonstrating an IC50 of 5.77 μM. This compound effectively reduces the production of key pro-inflammatory mediators, including nitrogen oxide (NO), reactive oxygen species (ROS), IL-1β, and IL-18, by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 has shown protective effects against dextran sulfate sodium (DSS)-induced colitis, making it a valuable tool for research into ulcerative colitis and related inflammatory conditions. -
COX-1 Inhibitor
Ethoxycoronarin D is a labdane diterpene that functions as a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 3.8 µM. This compound demonstrates significant anti-inflammatory activity and has potential applications in research related to pain management and various inflammatory conditions. Its selective inhibition of COX-1 may provide insights into the mechanisms underlying inflammation and pain pathways. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX
PPHP is a substrate designed for the quantitative assessment of cyclooxygenase (COX) enzymes. It specifically permits the measurement of peroxidase activity in both COX-1 and COX-2. This compound is valuable for research applications focused on inflammation, pain pathways, and the biochemical characterization of COX-related functions. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2 Inhibitor
PYZ18 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 7.07 μM. This compound demonstrates significant anti-inflammatory properties, making it a valuable tool in the study of inflammatory diseases. PYZ18 is suitable for research applications exploring COX-2 inhibition and its potential therapeutic effects. -
Anti-inflammatory Agent
NCX 2121 (NO-indomethacin) is an anti-inflammatory agent that acts primarily by inhibiting the production of pro-inflammatory mediators. It effectively inhibits the growth of PaCa-2 pancreatic cancer cells, exhibiting an IC50 value of 82 μM. This compound is utilized in research focusing on inflammation-related pathways and cancer biology. -
NF-κB/COX Inhibitor
Methoxycoronarin D is a potent inhibitor of NF-κB, demonstrating an IC50 value of 7.3 μM. Additionally, it selectively inhibits cyclooxygenase-1 (COX-1), with an IC50 value of 0.9 μM. This compound is relevant for research applications focused on inflammation and cancer due to its ability to modulate critical signaling pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX Inhibitor
11(R)-HEDE is a selective inhibitor of cyclooxygenase (COX), produced through the lipoxygenase-type reaction of 11Z,14Z-eicosadienoic acid. It is utilized in research studies to assess COX activity by measuring the absorbance of conjugated dienes spectrophotometrically. This compound is valuable for investigating the role of COX in various biological processes and disease models, contributing to the understanding of inflammatory pathways and potential therapeutic applications.
